A major advance in dementia screening is stirring new discussions about Alzheimer’s disease. Roughly one in nine American seniors is affected by Alzheimer’s, the most common type of dementia, which gradually undermines memory, thinking, and the ability to carry out everyday tasks.
Diagnosing Alzheimer’s remains challenging because there isn’t a single definitive test. However, a recent synthesis of 18 studies concludes that a simple blood test can reveal early signs of the brain disorder before any cognitive symptoms emerge.
The biomarker at the center of this progress is p-tau217. Its level in the bloodstream is strongly linked to two brain features characteristic of Alzheimer’s: amyloid plaques and tau tangles. This association has made p-tau217 a promising biomarker for detecting the disease early.
The new JAMA Neurology review supports using p-tau217 blood tests as a minimally invasive method for early identification, especially in settings where timely use of disease-modifying therapies could meaningfully slow or halt progression.
Dr. Liron Sinvani, who leads the Geriatric Hospitalist Service at Northwell Health and directs hospital-medicine research, called the finding a “major breakthrough.” He notes that a simple blood test indicating the presence of p-tau217 could flag individuals at very high risk of dementia even before symptoms arise.
Dementia symptoms commonly include memory lapses, trouble with familiar tasks, speech and comprehension difficulties, disorientation, poor judgment, and shifts in mood or personality. Clinicians diagnose Alzheimer’s through symptom assessment, medical history review, physical and neurological exams, and may use brain imaging or spinal fluid analysis to confirm or rule out other conditions.
Blood-based tests are gaining traction as a future tool for identifying Alzheimer’s. The U.S. Food and Drug Administration recently approved a new blood test for individuals aged 55 and older who present memory-related symptoms.
Typically, a doctor’s order is needed for p-tau217 tests, though there are online options advertised for around $229 that claim no physician or insurance involvement is required.
The JAMA analysis encompassed data from more than 7,800 participants and found that p-tau217 levels were markedly higher in people who were amyloid-positive than in those who were amyloid-negative, even in the absence of cognitive symptoms. Amyloid plaques refer to misfolded protein aggregates in the brain and are a hallmark of Alzheimer’s.
One challenge remains: there is no cure to eliminate amyloid plaques. Some treatments can reduce them in the early stages, but no definitive cure exists yet.
This raises a practical question: how many people would want to know they carry a high-risk biomarker before ever showing symptoms? While the technology isn’t yet ready for universal primetime, the hope is that early detection could pave the way for preventive or disease-modifying therapies as they become available.
Despite the absence of a cure, researchers and clinicians emphasize lifestyle strategies that may lower risk or slow progression. Adopting a healthy diet, maintaining regular physical activity, staying socially engaged, and keeping the brain mentally active are all associated with a more favorable dementia trajectory. Knowing one’s elevated risk could motivate individuals to adopt these measures sooner.
Would you consider undergoing a blood test to assess dementia risk before symptoms appear, knowing that effective treatments might be available in the future? Share your thoughts and concerns in the comments.
